… detection of erlotinib-sensitive NSCLC tumor cells with … erlotinib-mediated growth inhibition
in NSCLC tumor cell lines but may also serve as a potential biomarker in predicting erlotinib …

… cells to erlotinib followed by pemetrexed was mostly antagonistic in erlotinib-sensitive cells
and additive at best in erlotinib-… erlotinib-sensitive cells and an additive interaction in erlotinib-…

… cell culture models, where we showed that whereas the IC 50 of erlotinib sensitivity in untreated
versus cisplatin-treated cells … of erlotinib is substantially increased in the cisplatin-treated …

… In phase II clinical studies, oral erlotinib monotherapy has shown antitumor activity in
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian cancer …

… erlotinib sensitivity in sensitive cells. Similarly, silencing of Atg5 or Beclin-1 significantly
increased sensitivity to erlotinib in both sensitive cell … H1975 cell lines upon erlotinib exposure. …

… High-dose cisplatin treatment was shown to induce EGFR activation in lung cancer cell
lines (14). … upon the surviving cells sensitivity to erlotinib, either in wild-type or mutated-EGFR …

… of [ 11 C]erlotinib in differentiating erlotinib-sensitive tumors from erlotinib-insensitive or
erlotinib-resistant ones. To this end, four different human NSCLC cell lines were employed, two …

… , invasion and tumor sphere formation abilities in H1975 cells. … erlotinib resistance in the
erlotinib-sensitive NSCLC cell line … sensitivity of erlotinib-resistant NSCLC cell line H1975 to …

… We developed resistant cells (HCC4006ER) from erlotinib-sensitive HCC4006 cells
harboring an EGFR deletion mutation by chronic exposure to increasing concentrations of …

… cells might confer sensitivity to erlotinib through inhibition of mTOR signaling. As shown in
Figure 5c, erlotinib … Calu-6 cells after 24 h, but shLKB1 cells exhibited complete disruption of …